Related references
Note: Only part of the references are listed.Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab: triumphs and tribulations
R. Nahta et al.
ONCOGENE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
The insulin-like growth factor 1 receptor in cancer: Old focus, new future
Hermien Hartog et al.
EUROPEAN JOURNAL OF CANCER (2007)
Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo
Barbara Tanno et al.
CLINICAL CANCER RESEARCH (2006)
Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates Herceptin activity in vivo
Lori Jerome et al.
CANCER RESEARCH (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Towards novel anti-cancer strategies based on cystatin function
Daniel Keppler
CANCER LETTERS (2006)
The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells
A Carracedo et al.
CANCER CELL (2006)
Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer
D Sachdev et al.
CANCER RESEARCH (2006)
Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer
Jose Baselga et al.
ONCOLOGIST (2006)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2005)
Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin
L Yuste et al.
CANCER RESEARCH (2005)
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
K Scotlandi et al.
CANCER RESEARCH (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor
JM Carboni et al.
CANCER RESEARCH (2005)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
In vivo antitumor activity of NVP-AEW541 -: A novel, potent, and selective inhibitor of the IGF-IR kinase
C García-Echeverría et al.
CANCER CELL (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions
L Jerome et al.
ENDOCRINE-RELATED CANCER (2003)
The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells
JL Dupont et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
P21 (Waf1/Cip1) as a therapeutic target in breast and other cancers
RH Weiss
CANCER CELL (2003)
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
I Shin et al.
NATURE MEDICINE (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
FJ Esteva et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
A Esparis-Ogando et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells
AJ Butt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
A novel aspartyl proteinase from apocrine epithelia and breast tumors
E Caputo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation:: Receptor overexpression does not determine growth dependency
HA Lane et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Function of the IGF-I receptor in breast cancer
E Surmacz
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2000)
Share Paper
